Oncternal therapeutics, inc. (GTXI)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities
Net loss

-36,632

-34,188

-35,447

-39,986

-27,155

-38,418

-42,280

-41,353

-37,743

-30,439

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-14,213

-

-30,015

-69,816

-32,808

-39,411

-32,656

-36,658

-38,516

-42,111

-45,036

-30,998

-28,577

-27,075

-27,042

-41,487

-41,779

-33,294

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

867

507

712

1,063

1,590

2,197

2,603

3,065

3,134

3,151

2,864

2,780

2,906

2,957

3,070

2,978

2,915

2,620

2,110

1,618

2,632

4,428

5,692

6,188

5,134

3,733

2,997

3,019

2,580

2,648

2,926

3,254

3,909

4,226

0

0

0

Depreciation and amortization

-

-

-

-

-

46

46

47

46

47

46

42

36

28

24

23

30

43

52

66

86

102

137

187

267

384

487

599

690

750

817

867

932

1,040

0

0

0

Change in fair value of preferred stock warrants liability

-

1,268

0

0

0

-

-

-

-

-

-

-

-

-8,163

-10,892

-51,612

-8,596

-3,081

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash lease expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Directors' deferred compensation

-

-

-

-

-

166

166

166

167

166

164

156

143

132

120

114

112

113

116

120

124

125

124

124

125

135

146

155

166

169

0

0

0

-

-

-

-

Deferred revenue amortization

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,066

0

0

0

Impairment of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,598

0

0

0

Changes in operating assets and liabilities:
Directors' deferred compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Accounts receivable, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Inventory

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Prepaid and other assets

112

44

947

1,549

525

572

22

-266

-173

-251

-47

66

-55

-204

-1,073

-206

1,277

1,458

1,892

610

-749

577

130

269

-143

-399

-1,601

-1,232

-1,159

-1,857

267

415

276

849

0

0

0

Accounts payable

-2,004

-4,762

-4,244

-2,629

-882

675

670

870

1,225

1,384

1,228

-784

-389

838

1,039

590

465

-130

5

-195

-181

-296

-1,074

-804

-481

-899

46

334

163

488

378

323

279

371

0

0

0

Accrued expenses and other liabilities

-

-

-

-

-

-3,440

-644

1,822

3,628

1,980

4,687

2,439

2,127

950

-1,063

570

449

561

983

-1,285

-2,422

-2,231

-2,076

-4,076

-3,441

-4,246

-6,626

545

2,128

2,885

0

0

0

-

-

-

-

Accrued liabilities

-1,064

-1,255

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Change in operation lease liability

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred grant revenue

2,423

3,640

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-17,149

-16,746

-23,316

-27,204

-31,867

-39,346

-39,461

-35,117

-29,370

-23,460

-18,990

-21,869

-21,205

-20,778

-20,722

-19,444

-20,115

-20,035

-19,892

-20,633

-25,367

-28,759

-31,349

-36,674

-38,135

-43,971

-46,385

-43,945

-40,522

-37,109

-35,584

-34,886

-34,370

-33,089

0

0

0

Cash flows from investing activities
Acquisition related costs paid

-

2,155

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

90

0

0

0

-

-

-

-

5

5

4

7

32

0

0

0

-

-

-

-

54

0

0

0

Purchase of short-term investments, held to maturity

-

-

-

-

-

44,155

72,038

62,194

39,189

39,283

24,404

29,404

33,404

35,404

37,400

42,206

52,217

55,219

71,634

62,853

46,962

41,905

10,690

9,465

5,345

1,425

0

0

0

-

-

-

-

-

-

-

-

Purchase of short-term investments, held to maturity

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

Proceeds from maturities of short-term investments, held to maturity

-

-

-

-

-

72,038

57,254

39,189

30,743

24,159

29,404

33,404

36,864

37,645

54,863

57,117

70,454

71,434

0

0

0

-

-

-

-

9,270

12,270

13,695

13,205

14,630

0

0

0

-

-

-

-

Net cash used in investing activities

-

16,137

30,921

46,746

16,907

27,883

-14,786

-23,007

-8,448

-15,126

5,000

3,918

3,378

2,151

17,373

14,903

18,225

16,211

-20,752

-19,036

-25,093

-31,220

1,179

-1,270

2,157

9,237

25,728

24,029

20,686

21,405

1,026

-175

-1,508

-10,299

0

0

0

Cash flows from financing activities
Net proceeds from the issuance of common stock and warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

63,949

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Tax payments related to shares withheld for vested restricted stock units

-

-

-

-

-

672

672

643

643

156

154

154

154

208

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments on capital lease and financed equipment obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from exercise of stock options

16

14

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,226

1,229

891

124

85

0

0

0

-

-

-

-

Payments on capital lease and financed equipment obligations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

4

5

7

7

20

42

61

82

0

0

0

-

-

-

-

Net cash provided by financing activities

17

15

15

76

24,550

23,905

23,905

69,479

45,005

45,492

59,183

13,535

13,535

13,481

0

0

0

-

-

-

-

63,330

20,514

20,870

22,274

1,219

1,209

849

63

3

-7

-41

48,997

48,952

0

0

0

Net decrease in cash and cash equivalents

-916

-594

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of non-cash investing and financing activities:
Issuance of 2019 bonus awards with stock options in lieu of cash

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Asset acquisition costs included in accounts payable and accrued liabilities

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred financing costs included in accounts payable and accrued liabilities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

12,442

-30,342

11,355

7,187

6,906

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-3,559

-4,751

-2,100

-3,824

2,170

3,145

-8,269

3,351

-9,656

-17,074

-13,704

-33,515

-19,448

-19,067

-19,773

-15,701

-34,565

-35,102

13,119

5,564

0

0

0